Business Wire

ESI-GROUP

22.9.2021 14:26:12 CEST | Business Wire | Press release

Share
ESI Group: EMPHYSIS – The Missing Link Between Digital Simulation and Embedded Software

Regulatory News:

ESI Group (Paris:ESI):

The research project EMPHYSIS led by Bosch has delivered the new “eFMI standard” for model exchange to accelerate the model-based development of embedded software. On the 15th of September, this international collaborative project gathering 25 industrial and academic partners from different fields (like automotive and information technologies) situated in Belgium, Canada, France, Germany, and Sweden received the ITEA Award of Excellence for this unique achievement.

Better code with less effort through “eFMI” - the new model-exchange standard for embedded devices

When developing a new function, many engineers learn the hard way that their outstanding knowledge about the physics of their products is not enough by far to develop a function for an embedded target, due to the demanding requirements of safety-critical software, weak CPU magnitude and less memory than expected. While this might result in a never-to-be-realised excellent initial idea of operating and controlling their product in a much smarter way, at the same time it reveals the need for a link between digital simulation of physical processes and embedded software.

The aim of the EMPHYSIS project (Embedded Systems with Physical Models in the Production Code Software), led by Bosch, was to jointly come up with a new open standard that lays the foundation to develop new innovative tools. This that allows model-based functions to be realized directly in embedded software with better code and less effort. For this purpose, the project carried forward the idea of the very successful Functional Mock-up Interface (FMI) model exchange standard for simulation to develop FMI for embedded systems - the new “eFMI standard”. This enables a wide variety of advanced model-based approaches for control and diagnosis, such as solving a set of differential equations to compute a signal instead of measuring it via a sensor. By allowing a hardware sensor to be replaced with a piece of software, we significantly reduce the total cost.

« The EMPHYSIS project has achieved several outstanding results such as the automatic generation of efficient code for embedded devices. It shows the power of collaborative research projects to drive the adoption of a new standard and to generate significant productivity gains for the industry. »

– Jean-François Lavignon, ITEA Vice-chairman

The technical deep dive and benefits

Technically speaking, eFMI is innovative in that it provides a target-independent intermediate format defined by an entirely new language, the Guarded Algorithmic Language for Embedded Control: GALEC. This new programming language is able to guarantee that an algorithm described in this language can be translated into code that has:

  • static worst-case execution time;
  • static a-priori known memory demand; and
  • a statically proven absence of illegal memory access.

In other words: code that satisfies the hard requirements of automotive safety-critical embedded software, which also makes it applicable to many more, less restricted domains like robotics, industrial applications and consumer goods.

With eFMI and GALEC it is now possible to capture the computational essence of a model in a target-independent form that is a solid foundation for any code generator to produce highly optimised code for arbitrary runtime environments and software architectures. All this is cast into a traceable, extendable and verifiable container architecture that goes far beyond a simple exchange format.

The eFMI workflow allows developers to model a system on a higher level of abstraction, starting with a reusable, high-level, component-oriented and physically structured model. The tooling kit then automatically transforms this into a solution which can be better integrated into software.

The main benefits of this solution and the associated eFMI workflow are:

  • accelerating development time;
  • better use of domain experts by separating the concerns of physical modelling and embedded implementation;
  • overcoming vendor lock-in through eFMI being published as an open standard on GitHub; and
  • enabling new ways of OEM supplier collaborations.

Continuous success

An OEM Advisory Board has been established to gather additional requirements, input and use-cases and further disseminate the project’s results, helping to secure uptake and future innovations in new domains.

On 22 March 2021, right after the project’s end, the non-profit Modelica Association officially approved a new project under its umbrella to further develop, standardize and promote eFMI. With Robert Bosch GmbH, Dassault Systèmes, DLR Institute of System Dynamics and Control, dSPACE, ESI Group, ETAS GmbH and Modelon AB as initial members of the steering committee and Mercedes-Benz AG having joined recently, the first official release of eFMI 1.0 is targeted within 2021. Having developed 14 tools within EMPHYSIS, eFMI already has a broad foundation even before its official release.

« What makes us proud as a team is the fact that this success has been recognized not only by our business partners and the OEM Advisory Board representing the voice of the customer, but also by the ITEA organization.»

– Oliver Lenord, Research Engineer at the Model-based Systems Engineering department at Robert Bosch

For society as a whole, EMPHYSIS’ better software translates into safer and more efficient vehicles which are able to keep pace with customer demands and help tackle climate issues in the longer term. For the time being, however, the project’s message is clear: by taking full advantage of an equation-based, component-oriented modelling language with a good library, 90% gains can be made in productivity of model-based function development.

EMPHYSIS project partners

Belgium

  • Dana Belgium
  • Siemens Industry Software NV
  • University of Antwerp NEXOR

Canada

  • Maplesoft

France

  • CEA
  • Dassault Systemes SE
  • FH Electronics
  • Institut Polytechnique de Grenoble
  • OSE Engineering
  • Renault SAS
  • Siemens Industry Software SAS
  • SOBEN

Germany

  • AbsInt Angewandte Informatik GmbH
  • Deutsches Zentrum für Luft- und Raumfahrt (DLR) System Dynamics and Control
  • dSPACE GmbH
  • Elektronische Fahrwerksysteme GmbH
  • ESI ITI GmbH, part of ESI Group
  • ETAS GmbH
  • PIKETEC
  • Robert Bosch GmbH

Sweden

  • Dassault Systèmes AB
  • Linköping University
  • Modelon AB
  • RISE - Research institutes of Sweden SICS East
  • Volvo Personvagnar AB

About ITEA

ITEA is the Eureka Cluster for software innovation, enabling a large international community to collaborate in funded projects that turn innovative ideas into new businesses, jobs, economic growth and benefits for society. https://itea4.org

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information: https://www.esi-group.com/fr .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye